Combining histone deacetylase inhibitors (HDACis) with other therapies for cancer therapy

Anticancer activities of histone deacetylase inhibitors

Bolden, J. E., Peart, M. J., & Johnstone, R. W. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2133 · Cited by 2,919 · see citing works

Macrophages as regulators of tumour immunity and immunotherapy

DeNardo, D. G., & Ruffell, B. (2019) · Nature reviews. Immunology · doi:10.1038/s41577-019-0127-6 · Cited by 2,542 · see citing works

The DNA methyltransferase family: a versatile toolkit for epigenetic regulation

Lyko, F. (2017) · Nature Reviews Genetics · doi:10.1038/nrg.2017.80 · Cited by 1,476 · see citing works

Targeting the cancer epigenome for therapy

Jones, P. A., Issa, J. J., & Baylin, S. B. (2016) · Nature Reviews Genetics · doi:10.1038/nrg.2016.93 · Cited by 1,132 · see citing works

Targeting photodynamic and photothermal therapy to the endoplasmic reticulum enhances immunogenic cancer cell death

Li, W., Yang, J., Luo, L., Jiang, M., Qin, B., Yin, H., Zhu, C., Yuan, X., Zhang, J., Luo, Z., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11269-8 · Cited by 1,129 · see citing works

Histone Deacetylase 4 Controls Chondrocyte Hypertrophy during Skeletogenesis

Vega, R. B., Matsuda, K., Oh, J., Barbosa, A. C. C., Yang, X., Meadows, E., McAnally, J., Pomajzl, C., Shelton, J. M., Richardson, J. A., et al. (2004) · Cell · doi:10.1016/j.cell.2004.10.024 · Cited by 805 · see citing works

Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight

Ho, T. C. S., Chan, A. H. Y., & Ganesan, A. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00830 · Cited by 795 · see citing works

Opportunities and challenges of radiotherapy for treating cancer

Schaue, D., & McBride, W. H. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.120 · Cited by 784 · see citing works

Targeting the epigenetic regulation of antitumour immunity

Hogg, S. J., Beavis, P. A., Dawson, M. A., & Johnstone, R. W. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0077-5 · Cited by 653 · see citing works

Stimuli-Responsive Therapeutic Metallodrugs

Wang, X., Wang, X., Jin, S., Nafees, M., & Guo, Z. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00209 · Cited by 651 · see citing works

Epigenetic therapy in immune-oncology

Jones, P. A., Ohtani, H., Chakravarthy, A., & Carvalho, D. D. D. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0109-9 · Cited by 550 · see citing works

Metabolic and epigenetic regulation of T-cell exhaustion

Franco, F., Jaccard, A., Romero, P. J., Yu, Y.-R., & Ho, P. (2020) · Nature Metabolism · doi:10.1038/s42255-020-00280-9 · Cited by 457 · see citing works

Combining epigenetic drugs with other therapies for solid tumours — past lessons and future promise

Morel, D., Jeffery, D., Aspeslagh, S., Almouzni, G., & Postel-Vinay, S. C. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0267-4 · Cited by 457 · see citing works

Histone deacetylases and cancer

Barneda‐Zahonero, B., & Parra, M. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.07.003 · Cited by 449 · see citing works

Exosome-mediated siRNA delivery to suppress postoperative breast cancer metastasis

Zhao, L., Gu, C., Gan, Y. H., Shao, L., Chen, H., & Zhu, H. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.12.005 · Cited by 443 · see citing works

Epigenetic modulation and understanding of HDAC inhibitors in cancer therapy

Ramaiah, M. J., Tangutur, A. D., & Manyam, R. R. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119504 · Cited by 358 · see citing works

Class I histone deacetylases are major histone decrotonylases: evidence for critical and broad function of histone crotonylation in transcription

Wei, W., Liu, X., Chen, J., Gao, S., Lu, L., Zhang, H., Ding, G., Wang, Z., Chen, Z., Shi, T., et al. (2017) · Cell Research · doi:10.1038/cr.2017.68 · Cited by 304 · see citing works

NAD+-dependent deacetylation of H4 lysine 16 by class III HDACs

Vaquero, A., Sternglanz, R., & Reinberg, D. (2007) · Oncogene · doi:10.1038/sj.onc.1210617 · Cited by 291 · see citing works

Lactate production by Staphylococcus aureus biofilm inhibits HDAC11 to reprogramme the host immune response during persistent infection

Heim, C. E., Bosch, M. E., Yamada, K. J., Aldrich, A. L., Chaudhari, S. S., Klinkebiel, D. L., Gries, C. M., Alqarzaee, A. A., Li, Y., Thomas, V. C., et al. (2020) · Nature Microbiology · doi:10.1038/s41564-020-0756-3 · Cited by 242 · see citing works

Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade

Ye, Q., Vasilatos, S. N., Chen, L., Wu, H., Cao, Z., Fu, Y., Huang, M., Vlad, A., Lu, B., Oesterreich, S., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0451-5 · Cited by 226 · see citing works

Dual Inhibitors of Human DNA Topoisomerase II and Other Cancer-Related Targets

Skok, Ž., Zidar, N., Kikelj, D., & Ilaš, J. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00726 · Cited by 226 · see citing works

RGD peptide conjugated liposomal drug delivery system for enhance therapeutic efficacy in treating bone metastasis from prostate cancer

Wang, F., Chen, L., Zhang, R., Chen, Z., & Zhu, L. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.10.012 · Cited by 190 · see citing works

Histone Deacetylase (HDAC) Inhibitors with a Novel Connecting Unit Linker Region Reveal a Selectivity Profile for HDAC4 and HDAC5 with Improved Activity against Chemoresistant Cancer Cells

Marek, L., Hamacher, A., Hansen, F. K., Kuna, K., Gohlke, H., Kassack, M. U., & Kurz, T. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm301254q · Cited by 185 · see citing works

Redox-Activated Porphyrin-Based Liposome Remote-Loaded with Indoleamine 2,3-Dioxygenase (IDO) Inhibitor for Synergistic Photoimmunotherapy through Induction of Immunogenic Cell Death and Blockage of IDO Pathway

Liu, D., Chen, B., Mo, Y., Wang, Z., Qi, T., Zhang, Q., & Wang, Y. (2019) · Nano Letters · doi:10.1021/acs.nanolett.9b02306 · Cited by 185 · see citing works

Dual-Target Inhibitors Based on HDACs: Novel Antitumor Agents for Cancer Therapy

Liu, T., Wan, Y., Xiao, Y., Xia, C., & Duan, G. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00491 · Cited by 180 · see citing works

Discovery of first-in-class reversible dual small molecule inhibitors against G9a and DNMTs in hematological malignancies

José‐Eneriz, E. S., Agirre, X., Rabal, O., Vilas‐Zornoza, A., Sánchez-Arias, J. A., Miranda, E., Ugarte, A., Roa, S., Paiva, B., de Mendoza, A. E., et al. (2017) · Nature Communications · doi:10.1038/ncomms15424 · Cited by 176 · see citing works

Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells

Knox, T., Sahakian, E., Banik, D., Hadley, M., Palmer, E., Noonepalle, S., Kim, J., Powers, J., Gracia-Hernandez, M., Oliveira, V., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-42237-3 · Cited by 170 · see citing works

HDAC inhibition potentiates anti-tumor activity of macrophages and enhances anti-PD-L1-mediated tumor suppression

Li, X., Su, X., Liu, R., Pan, Y., Fang, J., Cao, L., Feng, C., Shang, Q., Chen, Y., Shao, C., et al. (2021) · Oncogene · doi:10.1038/s41388-020-01636-x · Cited by 170 · see citing works

A Review of Progress in Histone Deacetylase 6 Inhibitors Research: Structural Specificity and Functional Diversity

Zhang, X., Qin-Ma, Wu, H.-P., Khamis, M. Y., Li, Y., Ma, L., & Liu, H. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01782 · Cited by 160 · see citing works

HDAC2: a critical factor in health and disease

Krämer, O. H. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.09.007 · Cited by 157 · see citing works

HDAC5 is a repressor of angiogenesis and determines the angiogenic gene expression pattern of endothelial cells

Urbich, C., Rössig, L., Kaluza, D., Potente, M., Boeckel, J., Knau, A., Diehl, F., Geng, J.-G., Hofmann, W., Zeiher, A. M., et al. (2009) · Blood · doi:10.1182/blood-2009-01-196485 · Cited by 153 · see citing works

Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies

Inoue, S., MacFarlane, M., Harper, N. W., Wheat, L. M. C., Dyer, M. J. S., & Cohen, G. M. (2004) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401535 · Cited by 152 · see citing works

Chimeric HDAC inhibitors: Comprehensive review on the HDAC‐based strategies developed to combat cancer

Hesham, H. M., Lasheen, D. S., & Abouzid, K. A. M. (2018) · Medicinal Research Reviews · doi:10.1002/med.21505 · Cited by 149 · see citing works

Histone deacetylase function in CD4+ T cells

Ellmeier, W., & Seiser, C. (2018) · Nature reviews. Immunology · doi:10.1038/s41577-018-0037-z · Cited by 144 · see citing works

Valproic acid for the treatment of myeloid malignancies

Kuendgen, A., & Gattermann, N. (2007) · Cancer · doi:10.1002/cncr.22891 · Cited by 143 · see citing works

The tumour microenvironment and metabolism in renal cell carcinoma targeted or immune therapy

Lai, Y., Tang, F., Huang, Y., He, C., Chen, C., Zhao, J., Wu, W., & He, Z. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.29969 · Cited by 139 · see citing works

The Search for Potent, Small‐Molecule HDACIs in Cancer Treatment: A Decade After Vorinostat

Zagni, C., Floresta, G., Monciino, G., & Rescifina, A. (2017) · Medicinal Research Reviews · doi:10.1002/med.21437 · Cited by 138 · see citing works

Overcoming Physiological Barriers to Nanoparticle Delivery—Are We There Yet?

Thomas, O. S., & Weber, W. (2019) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2019.00415 · Cited by 138 · see citing works

Trend of Histone Deacetylase Inhibitors in Cancer Therapy: Isoform Selectivity or Multitargeted Strategy

Zhang, L., Han, Y., Jiang, Q., Wang, C., Chen, X., Li, X., Xu, F., Jiang, Y., Wang, Q., & Xu, W. (2014) · Medicinal Research Reviews · doi:10.1002/med.21320 · Cited by 130 · see citing works

Histone deacetylase (HDAC) inhibitor ACY241 enhances anti-tumor activities of antigen-specific central memory cytotoxic T lymphocytes against multiple myeloma and solid tumors

Bae, J. E., Hideshima, T., Tai, Y., Song, Y. Y., Richardson, P. G. G., Raje, N. S., Munshi, N. C., & Anderson, K. C. (2018) · Leukemia · doi:10.1038/s41375-018-0062-8 · Cited by 124 · see citing works

Platinum(IV) anticancer agents; are we en route to the holy grail or to a dead end?

Gibson, D. (2021) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2020.111353 · Cited by 123 · see citing works

New techniques and strategies in drug discovery

Du, J., Guo, J., Kang, D., Li, Z., Wang, G., Wu, J., Zhang, Z., Fang, H., Hou, X., Huang, Z., et al. (2020) · Chinese Chemical Letters · doi:10.1016/j.cclet.2020.03.028 · Cited by 122 · see citing works

Combination treatment of acute myeloid leukemia cells with DNMT and HDAC inhibitors: predominant synergistic gene downregulation associated with gene body demethylation

Blagitko‐Dorfs, N., Schlosser, P., Greve, G., Pfeifer, D., Meier, R., Baude, A., Brocks, D., Plass, C., & Lübbert, M. (2018) · Leukemia · doi:10.1038/s41375-018-0293-8 · Cited by 120 · see citing works

Author Correction: Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells

Knox, T. J., Sahakian, E., Banik, D., Hadley, M. M., Palmer, E., Noonepalle, S. K. R., Kim, J. S., Powers, J. J., Gracia-Hernandez, M., Oliveira, V. A., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-51403-6 · Cited by 118 · see citing works

HDAC11: a rising star in epigenetics

Liu, S., Wu, F., Jin, Y., Weiqin, C., & Xu, T. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110607 · Cited by 116 · see citing works

From molecular promise to preclinical results: HDAC inhibitors in the race for healthy aging drugs

McIntyre, R. L., Daniels, E. G., Molenaars, M., Houtkooper, R. H., & Janssens, G. E. (2019) · EMBO Molecular Medicine · doi:10.15252/emmm.201809854 · Cited by 115 · see citing works

Reprogramming Tumor-Associated Macrophages To Reverse EGFRT790M Resistance by Dual-Targeting Codelivery of Gefitinib/Vorinostat

Peng, H., Chen, B., Huang, W., Tang, Y., Jiang, Y., Zhang, W., & Huang, Y. (2017) · Nano Letters · doi:10.1021/acs.nanolett.7b03756 · Cited by 113 · see citing works

Hierarchical Multiplexing Nanodroplets for Imaging-Guided Cancer Radiotherapy via DNA Damage Enhancement and Concomitant DNA Repair Prevention

Jiang, W., Li, Q., Xiao, L., Dou, J., Liu, Y., Yu, W., Ma, Y., Li, X., You, Y., Tong, Z., et al. (2018) · ACS Nano · doi:10.1021/acsnano.8b01508 · Cited by 112 · see citing works

Design and Synthesis of Ligand Efficient Dual Inhibitors of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Based on Ruxolitinib and Vorinostat

Yao, L., Mustafa, N. B., Tan, E. C., Poulsen, A., Singh, P., Duong‐Thi, M., Lee, J. X. T., Ramanujulu, P. M., Chng, W. J., Yen, J. J. Y., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00678 · Cited by 111 · see citing works

Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections

Huang, Y., Dong, G., Li, H., Liu, N., Zhang, W., & Sheng, C. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00393 · Cited by 110 · see citing works

Deacetylation of Nonhistone Proteins by HDACs and the Implications in Cancer

Peng, L., & Seto, E. (2011) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-21631-2_3 · Cited by 105 · see citing works

Immune-related adverse events from combination immunotherapy in cancer patients: A comprehensive meta-analysis of randomized controlled trials

Zhang, B., Wu, Q., Zhou, Y. L., Guo, X., Ge, J., & Fu, J. (2018) · International Immunopharmacology · doi:10.1016/j.intimp.2018.08.014 · Cited by 103 · see citing works

An HDAC6-dependent surveillance mechanism suppresses tau-mediated neurodegeneration and cognitive decline

Trzeciakiewicz, H., Ajit, D., Tseng, J.-H., Chen, Y., Ajit, A., Tabassum, Z., Lobrovich, R., Peterson, C., Riddick, N. V., Itano, M. S., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19317-4 · Cited by 102 · see citing works

Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies

Liang, X., Zang, J., Li, X., Tang, S., Huang, M., Geng, M., Chou, C. J., Li, C., Cao, Y.-C., Xu, W., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01597 · Cited by 98 · see citing works

Sodium butyrate inhibits migration and induces AMPK‐mTOR pathway‐dependent autophagy and ROS‐mediated apoptosis via the miR‐139‐5p/Bmi‐1 axis in human bladder cancer cells

Wang, F., Wu, H., Fan, M., Yu, R., Zhang, Y., Liu, J., Zhou, X., Cai, Y., Huang, S., Hu, Z., et al. (2020) · The FASEB Journal · doi:10.1096/fj.201902626r · Cited by 97 · see citing works

Class I HDAC Inhibitors Display Different Antitumor Mechanism in Leukemia and Prostatic Cancer Cells Depending on Their p53 Status

Li, X., Peterson, Y. K., Inks, E. S., Himes, R. A., Li, J., Zhang, Y., Kong, X., & Chou, C. J. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00136 · Cited by 93 · see citing works

Histone deacetylase 6 regulates the immunosuppressive properties of cancer-associated fibroblasts in breast cancer through the STAT3–COX2-dependent pathway

Li, A., Chen, P., Leng, Y., & Kang, J. (2018) · Oncogene · doi:10.1038/s41388-018-0379-9 · Cited by 89 · see citing works

Histone Deacetylases 9 and 10 Are Required for Homologous Recombination

Kotian, S., Liyanarachchi, S., Zelent, A., & Parvin, J. D. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.c110.194233 · Cited by 88 · see citing works

Emerging role of histone deacetylase inhibitors as anti-breast-cancer agents

Ediriweera, M. K., Tennekoon, K. H., & Samarakoon, S. R. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.02.003 · Cited by 87 · see citing works

Discovery of a New Isoxazole-3-hydroxamate-Based Histone Deacetylase 6 Inhibitor SS-208 with Antitumor Activity in Syngeneic Melanoma Mouse Models

Shen, S., Hadley, M. M., Ustinova, K., Pavlı́ček, J., Knox, T. J., Noonepalle, S. K. R., Tavares, M. T., Zimprich, C., Zhang, G., Robers, M. B., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00946 · Cited by 85 · see citing works

Design of First-in-Class Dual EZH2/HDAC Inhibitor: Biochemical Activity and Biological Evaluation in Cancer Cells

Romanelli, A., Stazi, G., Fioravanti, R., Zwergel, C., Bello, E. D., Pomella, S., Perrone, C., Battistelli, C., Strippoli, R., Tripodi, M., et al. (2020) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.0c00014 · Cited by 81 · see citing works

EMA Review of Daunorubicin and Cytarabine Encapsulated in Liposomes (Vyxeos, CPX-351) for the Treatment of Adults with Newly Diagnosed, Therapy-Related Acute Myeloid Leukemia or Acute Myeloid Leukemia with Myelodysplasia-Related Changes

Tzogani, K., Penttilä, K., Lapveteläinen, T., Hemmings, R., Koenig, J., Freire, J., Márcia, S., Cole, S. P. C., Coppola, P., Flores, B., et al. (2020) · The Oncologist · doi:10.1634/theoncologist.2019-0785 · Cited by 81 · see citing works

Design of Hydrazide-Bearing HDACIs Based on Panobinostat and Their p53 and FLT3-ITD Dependency in Antileukemia Activity

Li, X., Jiang, Y., Peterson, Y. K., Xu, T., Himes, R. A., Luo, X., Yin, G., Inks, E. S., Dolloff, N. G., Halene, S., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00442 · Cited by 80 · see citing works

Small molecule HDAC inhibitors: Promising agents for breast cancer treatment

Huang, M., Zhang, J., Yan, C., Li, X., Zhang, J., & Ling, R. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.103184 · Cited by 79 · see citing works

Combination of a novel HDAC6 inhibitor ACY-241 and anti-PD-L1 antibody enhances anti-tumor immunity and cytotoxicity in multiple myeloma

Ray, A., Das, D. S., Song, Y. Y., Hideshima, T., Tai, Y., Chauhan, D., & Anderson, K. C. (2017) · Leukemia · doi:10.1038/leu.2017.322 · Cited by 76 · see citing works

HDAC3 is a potential validated target for cancer: An overview on the benzamide-based selective HDAC3 inhibitors through comparative SAR/QSAR/QAAR approaches

Adhikari, N., Amin, S. A., Trivedi, P., Jha, T., & Ghosh, B. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.08.081 · Cited by 76 · see citing works

pH-responsive hybrid quantum dots for targeting hypoxic tumor siRNA delivery

Zhu, H., Zhang, S., Ling, Y., Meng, G., Yang, Y. M., & Zhang, W. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.11.017 · Cited by 76 · see citing works

Epigenetics in modulating immune functions of stromal and immune cells in the tumor microenvironment

Pan, X., & Zheng, L. (2020) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-0505-9 · Cited by 75 · see citing works

Dual inhibitors of histone deacetylases and other cancer-related targets: A pharmacological perspective

Gao, Y., Zhang, H., Lirussi, F., Garrido, C., Ye, X., & Xie, T. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114224 · Cited by 73 · see citing works

Hydroxamic Acids Immobilized on Resins (HAIRs): Synthesis of Dual‐Targeting HDAC Inhibitors and HDAC Degraders (PROTACs)

Sinatra, L., Bandolik, J. J., Roatsch, M., Sönnichsen, M., Schoeder, C. T., Hamacher, A., Schöler, A., Borkhardt, A., Meiler, J., Bhatia, S., et al. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202006725 · Cited by 73 · see citing works

Histone deacetylases as targets for the treatment of neurodegenerative disorders: Challenges and future opportunities

Rodrigues, D. A., Pinheiro, P. D. S. M., Sagrillo, F. S., Bolognesi, M. L., & Fraga, C. A. M. (2020) · Medicinal Research Reviews · doi:10.1002/med.21701 · Cited by 72 · see citing works

Depletion of HDAC1, 7 and 8 by Histone Deacetylase Inhibition Confers Elimination of Pancreatic Cancer Stem Cells in Combination with Gemcitabine

Cai, M., Xu, X., Yan, S.-L., Sun, Z., Yin, Y., Wang, B., & Tu, Y. (2018) · Scientific Reports · doi:10.1038/s41598-018-20004-0 · Cited by 71 · see citing works

The histone deacetylase inhibitor valproic acid inhibits NKG2D expression in natural killer cells through suppression of STAT3 and HDAC3

Ni, L., Wang, L., Yao, C., Ni, Z., Liu, F., Gong, C., Zhu, X., Yan, X., Watowich, S. S., Lee, D. A., et al. (2017) · Scientific Reports · doi:10.1038/srep45266 · Cited by 70 · see citing works

Facile Construction of i-Motif DNA-Conjugated Gold Nanostars as Near-Infrared and pH Dual-Responsive Targeted Drug Delivery Systems for Combined Cancer Therapy

Miao, D., Yu, Y., Chen, Y., Liu, Y., & Su, G. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b01159 · Cited by 69 · see citing works

Discovery of Novel Indoleamine 2,3-Dioxygenase 1 (IDO1) and Histone Deacetylase (HDAC) Dual Inhibitors

Fang, K., Dong, G., Li, Y., He, S., Wu, Y., Wu, S., Wang, W., & Sheng, C. (2018) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.7b00487 · Cited by 64 · see citing works

Modulation of SIRT1-mediated signaling cascades in the liver contributes to the amelioration of nonalcoholic steatohepatitis in high fat fed middle-aged LDL receptor knockout mice by dihydromyricetin

Zeng, Y., Hua, Y. Q., Wang, W., Zhang, H., & Xu, X. L. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.113927 · Cited by 63 · see citing works

Novel porphyrazine-based photodynamic anti-cancer therapy induces immunogenic cell death

Turubanova, V. D., Mishchenko, T. A., Владимировна, Б. И., Efimova, I., Peskova, N. N., Klapshina, L. G., Lermontova, S. A., Bachert, C., Krysko, O., Vedunova, M. V., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-86354-4 · Cited by 63 · see citing works

Rational Design of Suprastat: A Novel Selective Histone Deacetylase 6 Inhibitor with the Ability to Potentiate Immunotherapy in Melanoma Models

Noonepalle, S. K. R., Shen, S., Ptáček, J., Tavares, M. T., Zhang, G., Stránský, J., Pavlı́ček, J., Ferreira, G. M., Hadley, M. M., Pelaez, G. D., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00567 · Cited by 61 · see citing works

Novel Carboline Fungal Histone Deacetylase (HDAC) Inhibitors for Combinational Treatment of Azole-Resistant Candidiasis

Li, Z., Tu, J., Han, G., Liu, N., & Sheng, C. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01763 · Cited by 60 · see citing works

Protective role of sirtuin3 against oxidative stress and NLRP3 inflammasome in cholesterol accumulation and foam cell formation of macrophages with ox-LDL-stimulation

Ding, Y., Gong, W., Zhang, S., Shen, J., Liu, X., Wang, Y., Chen, Y., & Meng, G. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114665 · Cited by 58 · see citing works

Histone deacetylase inhibitor targets CD123/CD47-positive cells and reverse chemoresistance phenotype in acute myeloid leukemia

Yan, B., Chen, Q., Shimada, K., Tang, M., Li, H., Gurumurthy, A., Khoury, J. D., Xu, B., Huang, S., & Qiu, Y. (2018) · Leukemia · doi:10.1038/s41375-018-0279-6 · Cited by 57 · see citing works

Issue Information

(2020) · The FASEB Journal · doi:10.1096/fsb2.21134 · Cited by 57 · see citing works

Interleukin-10 inhibits neuroinflammation-mediated apoptosis of ventral mesencephalic neurons via JAK-STAT3 pathway

Zhu, Y., Liu, Z., Peng, Y.-P., & Qiu, Y. (2017) · International Immunopharmacology · doi:10.1016/j.intimp.2017.07.017 · Cited by 56 · see citing works

Histone deacetylase 2 regulates ULK1 mediated pyroptosis during acute liver failure by the K68 acetylation site

Wang, Y., Chen, Q., Jiao, F., Shi, C., Pei, M., Wang, L., & Gong, Z. (2021) · Cell Death and Disease · doi:10.1038/s41419-020-03317-9 · Cited by 55 · see citing works

Curcumin regulates peroxisome proliferator-activated receptor-γ coactivator-1α expression by AMPK pathway in hepatic stellate cells in vitro

Zhai, X., Qiao, H., Guan, W., Li, Z., Cheng, Y., Jia, X., & Zhou, Y. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.10.055 · Cited by 53 · see citing works

Class IIa HDACs regulate learning and memory through dynamic experience-dependent repression of transcription

Zhu, Y., Huang, M., Bushong, E. A., Phan, S., Uytiepo, M., Beutter, E., Boemer, D., Tsui, K. C., Ellisman, M. H., & Maximov, A. (2019) · Nature Communications · doi:10.1038/s41467-019-11409-0 · Cited by 53 · see citing works

Synthesis of Artemisinin–Estrogen Hybrids Highly Active against HCMV, P. falciparum, and Cervical and Breast Cancer

Fröhlich, T., Kiss, A., Woelfling, J., Mernyák, E., Kulmány, Á. E., Minorics, R., Zupkó, I., Leidenberger, M., Friedrich, O., Kappes, B., et al. (2018) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.8b00381 · Cited by 52 · see citing works

Rattle-Type Gold Nanorods/Porous-SiO2 Nanocomposites as Near-Infrared Light-Activated Drug Delivery Systems for Cancer Combined Chemo–Photothermal Therapy

Yu, Y., Zhou, M., Zhang, W., Huang, L., Miao, D., Zhu, H., & Su, G. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b01298 · Cited by 52 · see citing works

HDACis (class I), cancer stem cell, and phytochemicals: Cancer therapy and prevention implications

Bayat, S., Khaniani, M. S., Choupani, J., Alivand, M. R., & Derakhshan, S. M. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.11.065 · Cited by 50 · see citing works

Preclinical Studies Support Combined Inhibition of BET Family Proteins and Histone Deacetylases as Epigenetic Therapy for Cutaneous T-Cell Lymphoma

Zhao, L., Okhovat, J., Hong, E., Kim, Y. H., & Wood, G. S. (2018) · Neoplasia · doi:10.1016/j.neo.2018.11.006 · Cited by 49 · see citing works

Synergistic antitumour activity of HDAC inhibitor SAHA and EGFR inhibitor gefitinib in head and neck cancer: a key role for ΔNp63α

Citro, S., Bellini, A., Miccolo, C., Ghiani, L., Carey, T. E., & Chiocca, S. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0394-9 · Cited by 49 · see citing works

Sirtuin-1 in immunotherapy: A Janus-headed target

Chadha, S., Wang, L., Hancock, W. W., & Beier, U. H. (2019) · Journal of Leukocyte Biology · doi:10.1002/jlb.2ru1118-422r · Cited by 46 · see citing works

Isoform-specific characterization of class I histone deacetylases and their therapeutic modulation in pulmonary hypertension

Chelladurai, P., Dabral, S., Basineni, S. R., Chen, C.-N., Schmoranzer, M., Bender, N., Feld, C., Nötzold, R. R., Dobreva, G. D., Wilhelm, J., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-69737-x · Cited by 44 · see citing works

HDAC inhibitors tested in phase III trial

Romero, D. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0224-2 · Cited by 43 · see citing works

RNH1 regulation of reactive oxygen species contributes to histone deacetylase inhibitor resistance in gastric cancer cells

Zhu, Y., Das, K., Wu, J., Lee, M., & Tan, P. B. O. (2013) · Oncogene · doi:10.1038/onc.2013.104 · Cited by 43 · see citing works

Selective inhibition of cancer cell self-renewal through a Quisinostat-histone H1.0 axis

Morales, C., Wu, M., Hobor, S., Wainwright, E. N., Martin, M. J., Patel, H., Grey, W., Gronroos, E. C., Howell, S. A., Carvalho, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15615-z · Cited by 43 · see citing works

Phosphorylation of cofilin-1 by ERK confers HDAC inhibitor resistance in hepatocellular carcinoma cells via decreased ROS-mediated mitochondria injury

Liao, P.-H., Hsu, H.-H., Chen, T.-S., Chen, M., Day, C.-H., Tu, C.-C., Lin, Y.-M., Tsai, F.-J., Kuo, W.-W., & Huang, C.-Y. (2016) · Oncogene · doi:10.1038/onc.2016.357 · Cited by 42 · see citing works

Biochemical, biological and structural properties of romidepsin ( FK 228) and its analogs as novel HDAC / PI 3K dual inhibitors

Saijo, K., Imamura, J., Narita, K., Oda, A., Shimodaira, H., Katoh, T., & Ishioka, C. (2014) · Cancer Science · doi:10.1111/cas.12585 · Cited by 41 · see citing works

Targeting miRNAs by histone deacetylase inhibitors (HDACi): Rationalizing epigenetics-based therapies for breast cancer

Ediriweera, M. K., & Cho, S. K. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107437 · Cited by 41 · see citing works

Epigenetic regulation of p62/SQSTM1 overcomes the radioresistance of head and neck cancer cells via autophagy-dependent senescence induction

Lee, M., Nam, H. Y., Kang, H., Lee, W. H., Lee, G., Sung, G., Han, M. W., Cho, K., Chang, E., Choi, K., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03539-5 · Cited by 41 · see citing works

Identification and Characterization of AES-135, a Hydroxamic Acid-Based HDAC Inhibitor That Prolongs Survival in an Orthotopic Mouse Model of Pancreatic Cancer

Shouksmith, A. E., Shah, F., Grimard, M., Gawel, J. M., Raouf, Y. S., Geletu, M., Berger‐Becvar, A., de Araujo, E. D., Luchman, H. A., Heaton, W. L., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01957 · Cited by 40 · see citing works

Synergistic antitumor activity of artesunate and HDAC inhibitors through elevating heme synthesis via synergistic upregulation of ALAS1 expression

Chen, C., Chen, K., Feng, Z., Wen, X., & Sun, H. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.05.001 · Cited by 40 · see citing works

Zn2+-Dependent Histone Deacetylases in Plants: Structure and Evolution

Yruela, I., Moreno–Yruela, C., & Olsen, C. A. (2021) · Trends in Plant Science · doi:10.1016/j.tplants.2020.12.011 · Cited by 40 · see citing works

On the function of the internal cavity of histone deacetylase protein 8: R37 is a crucial residue for catalysis

Haider, S. M., Joseph, C. G., Neidle, S., Fierke, C. A., & Fuchter, M. J. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.01.128 · Cited by 39 · see citing works

BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia

Herbaux, C., Kornauth, C., Poulain, S., Chong, S. J. F., Collins, M. C., Valentin, R., Hackett, L. R., Tournilhac, O., Lemonnier, F., Dupuis, J., et al. (2021) · Blood · doi:10.1182/blood.2020007303 · Cited by 39 · see citing works

A Multitargeted Approach: Organorhodium Anticancer Agent Based on Vorinostat as a Potent Histone Deacetylase Inhibitor

Hanif, M., Arshad, J. Z., Astin, J. W., Rana, Z., Zafar, A., Movassaghi, S., Leung, E. Y., Patel, K. D., Söhnel, T., Reynisson, J., et al. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202005758 · Cited by 38 · see citing works

Histone deacetylase inhibition prevents the growth of primary and metastatic osteosarcoma

McGuire, J., Nerlakanti, N., Lo, C. H., Tauro, M., Utset‐Ward, T. J., Reed, D. R., & Lynch, C. C. (2020) · International Journal of Cancer · doi:10.1002/ijc.33046 · Cited by 38 · see citing works

Histone deacetylase 1 and 2 in mesenchymal tumors

Pacheco, M., & Nielsen, T. O. (2011) · Modern Pathology · doi:10.1038/modpathol.2011.157 · Cited by 37 · see citing works

Synthesis and Antileukemic Activities of Piperlongumine and HDAC Inhibitor Hybrids against Acute Myeloid Leukemia Cells

Liao, Y., Niu, X., Chen, B., Edwards, H. J., Xu, L., Xie, C., Lin, H., Polin, L., Taub, J. W., Ge, Y., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00772 · Cited by 37 · see citing works

Design and Synthesis of C3‐Substituted β‐Carboline‐Based Histone Deacetylase Inhibitors with Potent Antitumor Activities

Ling, Y., Feng, J., Luo, L., Guo, J., Peng, Y., Wang, T., Ge, X., Xu, Q., Wang, X., Dai, H., et al. (2017) · ChemMedChem · doi:10.1002/cmdc.201700133 · Cited by 37 · see citing works

Mesoporous silica-coated gold nanostars with drug payload for combined chemo-photothermal cancer therapy

Su, G., Miao, D., Yu, Y., Zhou, M., Jiao, P., Cao, X., Yan, B., & Zhu, H. (2018) · Journal of drug targeting · doi:10.1080/1061186x.2018.1499746 · Cited by 37 · see citing works

Cancer Chemoradiotherapy Duo: Nano-Enabled Targeting of DNA Lesion Formation and DNA Damage Response

Jiang, W., Li, Q., Zhu, Z., Wang, Q., Dou, J., Zhao, Y., Lv, W., Zhong, F., Yao, Y., Zhang, G., et al. (2018) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.8b10901 · Cited by 37 · see citing works

Design and Synthesis of Novel Epigenetic Inhibitors Targeting Histone Deacetylases, DNA Methyltransferase 1, and Lysine Methyltransferase G9a with In Vivo Efficacy in Multiple Myeloma

Rabal, O., José‐Eneriz, E. S., Agirre, X., Sánchez-Arias, J. A., de Miguel, I., Ordóñez, R., Gárate, L., Miranda, E., Sáez, E., Vilas‐Zornoza, A., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c02255 · Cited by 36 · see citing works

Class I and II Histone Deacetylase Inhibitors Differentially Regulate Thermogenic Gene Expression in Brown Adipocytes

Rajan, A., Shi, H., & Xue, B. (2018) · Scientific Reports · doi:10.1038/s41598-018-31560-w · Cited by 35 · see citing works

Blockade of myeloid-derived suppressor cell function by valproic acid enhanced anti-PD-L1 tumor immunotherapy

Adeshakin, A. O., Yan, D., Zhang, M., Wang, L., Adeshakin, F. O., Liu, W., & Wan, X. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.11.155 · Cited by 35 · see citing works

Combined inhibition of histone deacetylases and BET family proteins as epigenetic therapy for nerve injury-induced neuropathic pain

Borgonetti, V., & Galeotti, N. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105431 · Cited by 34 · see citing works

VEGF-PKD1-HDAC7 signaling promotes endothelial progenitor cell migration and tube formation

Yu, D., Chen, W., Ren, J., Zhang, T., Yang, K., Wu, G., & Liu, H. (2013) · Microvascular Research · doi:10.1016/j.mvr.2013.10.006 · Cited by 33 · see citing works

Remarks on the mechanism of phase-transfer catalyzed carbanion generation in two-phase systems

Mąkosza, M., & Kryklowa, I. (1999) · Tetrahedron · doi:10.1016/s0040-4020(99)00215-x · Cited by 32 · see citing works

Identification of Histone deacetylase (HDAC)‐Associated Proteins with DNA‐Programmed Affinity Labeling

Zhang, J., Peng, J., Huang, Y., Meng, L. H., Li, Q., Xiong, F., & Li, X. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202001205 · Cited by 32 · see citing works

HDAC–Bax Multiple Ligands Enhance Bax-Dependent Apoptosis in HeLa Cells

Tao, L., Zhou, Y., Elhassan, R. M., Hou, X., Yang, X., & Fang, H. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01454 · Cited by 32 · see citing works

Enhancing the Efficacy of Melanocortin 1 Receptor-Targeted Radiotherapy by Pharmacologically Upregulating the Receptor in Metastatic Melanoma

Li, M., Liu, D., Lee, D., Kapoor, S., Gibson-Corley, K. N., Quinn, T. P., Sagastume, E. A., Mott, S. L., Walsh, S. A., Acevedo, M. R., et al. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b00512 · Cited by 31 · see citing works

Hybrids from Farnesylthiosalicylic Acid and Hydroxamic Acid as Dual Ras‐Related Signaling and Histone Deacetylase (HDAC) Inhibitors: Design, Synthesis and Biological Evaluation

Ling, Y., Wang, X., Wang, C., Xu, C., Zhang, W., Zhang, Y., & Zhang, Y. (2015) · ChemMedChem · doi:10.1002/cmdc.201500019 · Cited by 30 · see citing works

Histone Deacetylase Inhibitor Sensitizes ERCC1-High Non-small-Cell Lung Cancer Cells to Cisplatin via Regulating miR-149

He, Y., Chen, D., Yi, Y., Zeng, S., Liu, S., Li, P., Xie, H., Yu, P. Y., Jiang, G., & Liu, H. (2020) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2020.05.001 · Cited by 30 · see citing works

Histone chaperone exploits intrinsic disorder to switch acetylation specificity

Danilenko, N., Lercher, L., Kirkpatrick, J., Gabel, F., Codutti, L., & Carlomagno, T. (2019) · Nature Communications · doi:10.1038/s41467-019-11410-7 · Cited by 29 · see citing works

Molecular imaging HDACs class IIa expression-activity and pharmacologic inhibition in intracerebral glioma models in rats using PET/CT/(MRI) with [18F]TFAHA

Laws, M. T., Bonomi, R. E., Kamal, S., Gelovani, D. J., Llaniguez, J. T., Potukutchi, S., Lu, X., Mangner, T. J., & Gelovani, J. G. (2019) · Scientific Reports · doi:10.1038/s41598-019-40054-2 · Cited by 29 · see citing works

The important role of histone deacetylases in modulating vascular physiology and arteriosclerosis

Zhao, T. C., Wang, Z., & Zhao, Y. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.04.020 · Cited by 29 · see citing works

In Silico and in Vitro Interactions between Short Chain Fatty Acids and Human Histone Deacetylases.

Ho, R.-H., Chan, J., Fan, H., Kioh, D. Y. Q., Lee, B.-W., & Chan, E. C. (2017) · Biochemistry · doi:10.1021/acs.biochem.7b00508 · Cited by 28 · see citing works

Polyphotosensitizer nanogels for GSH-responsive histone deacetylase inhibitors delivery and enhanced cancer photodynamic therapy.

Liu, N., Liu, H., Chen, H.-R., Wang, G., Teng, H., & Chang, Y.-L. (2019) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/j.colsurfb.2019.110753 · Cited by 28 · see citing works

Overcoming inherent resistance to histone deacetylase inhibitors in multiple myeloma cells by targeting pathways integral to the actin cytoskeleton

Mithraprabhu, S., Khong, T. T., & Spencer, A. G. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.98 · Cited by 27 · see citing works

Innovative DNA-Targeted Metallo-prodrug Strategy Combining Histone Deacetylase Inhibition with Oxidative Stress

McGivern, T. J. P., Slator, C., Kellett, A., & Marmion, C. J. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00652 · Cited by 27 · see citing works

Role of class I histone deacetylases in the regulation of maspin expression in prostate cancer

Shankar, E., Pandey, M., Verma, S., Abbas, A., Candamo, M., Kanwal, R., Shukla, S., MacLennan, G. T., & Gupta, S. (2020) · Molecular Carcinogenesis · doi:10.1002/mc.23214 · Cited by 27 · see citing works

Multitarget Inhibition of Histone Deacetylase (HDAC) and Phosphatidylinositol‐3‐kinase (PI3K): Current and Future Prospects

Rodrigues, D. A., Pinheiro, P. D. S. M., & Fraga, C. A. M. (2020) · ChemMedChem · doi:10.1002/cmdc.202000643 · Cited by 27 · see citing works

Integrating Epigenetic Modulators in Nanofibers for Synergistic Gastric Cancer Therapy via Epigenetic Reprogramming

Wang, L., Zhang, C., Hong, Y., Li, X., Li, T., Gao, A., Pan, S., Liu, B., Jin, H., & Cui, D. (2020) · Nano Letters · doi:10.1021/acs.nanolett.0c03665 · Cited by 27 · see citing works

Quantitative Proteomics Analysis Reveals Molecular Networks Regulated by Epidermal Growth Factor Receptor Level in Head and Neck Cancer

Yang, W., Cai, Q., Lui, V. W. Y., Everley, P. A., Kim, J., Bhola, N. E., Quesnelle, K. M., Zetter, B. R., Steen, H., Freeman, M. R., et al. (2010) · Journal of Proteome Research · doi:10.1021/pr901211j · Cited by 26 · see citing works

Histone Deacetylase Inhibitor (HDACi) Conjugated Polycaprolactone for Combination Cancer Therapy

Kularatne, R. N., Washington, K. E., Bulumulla, C., Calubaquib, E. L., Biewer, M. C., Oupický, D., & Stefan, M. C. (2018) · Biomacromolecules · doi:10.1021/acs.biomac.8b00221 · Cited by 26 · see citing works

The Development Process: from SAHA to Hydroxamate HDAC Inhibitors with Branched CAP Region and Linear Linker

Yang, F., Zhao, N., Hu, Y., Jiang, C., & Zhang, H. (2019) · Chemistry & Biodiversity · doi:10.1002/cbdv.201900427 · Cited by 26 · see citing works

A Translational Study of a Silicon Phthalocyanine Substituted with a Histone Deacetylase Inhibitor for Photodynamic Therapy

Aru, B., Günay, A., Şenkuytu, E., Demirel, G. Y., Gürek, A. G., & Atílla, D. (2020) · ACS Omega · doi:10.1021/acsomega.0c03180 · Cited by 26 · see citing works

Histone deacetylase inhibitor ITF2357 leads to apoptosis and enhances doxorubicin cytotoxicity in preclinical models of human sarcoma

Martile, M. D., Desideri, M., Tupone, M. G., Buglioni, S., Antoniani, B., Mastroiorio, C., Falcioni, R., Ferraresi, V., Baldini, N., Biagini, R., et al. (2018) · Oncogenesis · doi:10.1038/s41389-018-0026-x · Cited by 25 · see citing works

Enhanced antitumoral activity of TLR7 agonists via activation of human endogenous retroviruses by HDAC inhibitors

Díaz-Carballo, D., Saka, S., Acikelli, A. H., Homp, E., Erwes, J., Demmig, R., Klein, J., Schröer, K., Malak, S., D’Souza, F., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-01800-3 · Cited by 25 · see citing works

Inhibition of Class IIa HDACs improves endothelial barrier function in endotoxin‐induced acute lung injury

Kovács‐Kása, A., Kovács, L., Cherian‐Shaw, M., Patel, V. S., Meadows, M. L., Fulton, D. J., Su, Y., & Verin, A. D. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.30053 · Cited by 24 · see citing works

Class I histone deacetylase inhibition promotes CD8 T cell activation in ovarian cancer

McCaw, T. R., Goel, N., Brooke, D. J., Katre, A. A., Londoño, A. I., Smith, H. J., Randall, T. D., & Arend, R. C. (2020) · Cancer Medicine · doi:10.1002/cam4.3337 · Cited by 24 · see citing works

HDAC6 inhibitor, ACY1215 suppress the proliferation and induce apoptosis of gallbladder cancer cells and increased the chemotherapy effect of gemcitabine and oxaliplatin

Ruan, Y., Wang, L., & Lu, Y. (2021) · Drug Development Research · doi:10.1002/ddr.21780 · Cited by 24 · see citing works

HDAC Regulates Transcription at the Outset of Axolotl Tail Regeneration

Voss, S. R., Ponomareva, L. V., Dwaraka, V. B., Pardue, K. E., Baddar, N. W. A. H., Rodgers, A. K., Woodcock, M. R., Qiu, Q., Crowner, A., Blichmann, D., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-43230-6 · Cited by 23 · see citing works

SAHA attenuates Takotsubo-like myocardial injury by targeting an epigenetic Ac/Dc axis

Khurana, I., Maxwell, S., Royce, S. G., Mathiyalagan, P., Karagiannis, T. C., Mazarakis, N., Vongsvivut, J. P., Kaipananickal, H., Okabe, J., Al‐Hasani, K., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00546-y · Cited by 23 · see citing works

Epigenetic mechanisms underlying the therapeutic effects of HDAC inhibitors in chronic myeloid leukemia

Lernoux, M., Schnekenburger, M., Dicato, M. A., & Diederich, M. F. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.113698 · Cited by 21 · see citing works

Studying Histone Deacetylase Inhibition and Apoptosis Induction of Psammaplin A Monomers with Modified Thiol Group

Bao, Y. J., Xu, Q., Wang, L., Wei, Y., Hu, B., Wang, J., Liu, D., Zhao, L., & Jing, Y. (2021) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.0c00369 · Cited by 20 · see citing works

Molecular Signatures Associated with Treatment of Triple-Negative MDA-MB231 Breast Cancer Cells with Histone Deacetylase Inhibitors JAHA and SAHA

Librizzi, M., Caradonna, F., Cruciata, I., Dȩbski, J., Sansook, S., Dadlez, M., Spencer, J., & Luparello, C. (2017) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.7b00269 · Cited by 19 · see citing works

Combined inhibition of HDAC and DNMT1 induces p85α/MEK-mediated cell cycle arrest by dual target inhibitor 208 in U937 cells

Ren, Y., Sun, Q., Yuan, Z., & Jiang, Y. (2019) · Chinese Chemical Letters · doi:10.1016/j.cclet.2019.03.029 · Cited by 17 · see citing works

Epigenetic control of tumor angiogenesis

Ribatti, D., & Tamma, R. (2019) · Microcirculation · doi:10.1111/micc.12602 · Cited by 17 · see citing works

Histone deacetylase inhibitors potentiate photochemotherapy in cutaneous T-cell lymphoma MyLa cells

Sung, J. J., Ververis, K., & Karagiannis, T. C. (2014) · Journal of Photochemistry and Photobiology B Biology · doi:10.1016/j.jphotobiol.2014.01.009 · Cited by 16 · see citing works

Design, synthesis, and biological evaluation of target water‐soluble hydroxamic acid‐based HDACi derivatives as prodrugs

Li, J., Zhu, Y., Xie, M., Zhang, Q. Y., & Du, W. (2019) · Chemical Biology & Drug Design · doi:10.1111/cbdd.13577 · Cited by 16 · see citing works

Targeted therapy for mTORC1-driven tumours through HDAC inhibition by exploiting innate vulnerability of mTORC1 hyper-activation

Yang, F., Sun, S., Wang, C., Haas, M., Yeo, S. K., & Guan, J. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0839-1 · Cited by 16 · see citing works

Differential Response of Human Hepatocyte Chromatin to HDAC Inhibitors as a Function of Microenvironmental Glucose Level

Felisbino, M. B., da Costa, T. A., Gatti, M. S. V., & Mello, M. L. S. (2016) · Journal of Cellular Physiology · doi:10.1002/jcp.25343 · Cited by 15 · see citing works

Polyethylene Glycol-Encapsulated Histone Deacetylase Inhibitor Drug-Composite Nanoparticles for Combination Therapy with Artesunate

Goswami, U., Kandimalla, R., Kalita, S., Chattopadhyay, A., & Ghosh, S. S. (2018) · ACS Omega · doi:10.1021/acsomega.8b02105 · Cited by 15 · see citing works

Histone deacetylases inhibitors as new potential drugs against Leishmania braziliensis, the main causative agent of new world tegumentary leishmaniasis

de Souza, L. Â., Bastos, M. S. E., Agripino, J. D. M., Onofre, T. S., Calla, L. F. A., Heimburg, T., Ghazy, E., Bayer, T., da Silva, V. H. F., Ribeiro, P. D., et al. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114191 · Cited by 14 · see citing works

Resistance to histone deacetylase inhibitors confers hypersensitivity to oncolytic reovirus therapy

Islam, S., Espitia, C. M., Persky, D. O., Carew, J. S., & Nawrocki, S. T. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020002297 · Cited by 14 · see citing works

Novel dual-mode antitumor chlorin-based derivatives as potent photosensitizers and histone deacetylase inhibitors for photodynamic therapy and chemotherapy

Zhang, X., Liu, M., Luo, Y., Han, G., Ma, Z., Huang, F., Wang, Y., Miao, Z., Zhang, W., Sheng, C., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113363 · Cited by 12 · see citing works

A phase II clinical study of 13‐deoxy, 5‐iminodoxorubicin (GPX‐150) with metastatic and unresectable soft tissue sarcoma

Tine, B. A. V., Agulnik, M., Olson, R. D., Walsh, G. M., Klausner, A., Frank, N. E., Talley, T. T., & Milhem, M. M. (2019) · Cancer Medicine · doi:10.1002/cam4.2136 · Cited by 11 · see citing works

Development of Ligand-Drug Conjugates Targeting Melanoma through the Overexpressed Melanocortin 1 Receptor

Zhou, Y., Haghighi, S. M., Liu, Z., Wang, L., Hruby, V. J., & Cai, M. (2020) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00072 · Cited by 11 · see citing works

The mechanism and potential targets of class II HDACs in angiogenesis

Hou, F., Li, D., Yu, H., & Kong, Q. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26476 · Cited by 10 · see citing works

EGFR-Targeted Magnetic Nanovectors Recognize, in Vivo, Head and Neck Squamous Cells Carcinoma-Derived Tumors

Colecchia, D., Nicolato, E., Ravagli, C., Faraoni, P., Strambi, A., Rossi, M., Doumett, S., Mosconi, E., Locatelli, E., Franchini, M. C., et al. (2017) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.7b00278 · Cited by 6 · see citing works

Arsenic Sulfide Nanoformulation Induces Megakaryocytic Differentiation through Histone Deacetylase Inhibition

Jia, M., Wang, T., Xu, S., Liu, J., Wen, T., Meng, J., & Xu, H. (2019) · Advanced Therapeutics · doi:10.1002/adtp.201900151 · Cited by 6 · see citing works

Targeting histone deacetylases for combination therapies in neuroendocrine tumors

Gagliano, T., & Brancolini, C. (2020) · Cancer Gene Therapy · doi:10.1038/s41417-020-00260-x · Cited by 6 · see citing works

HSP72 functionally inhibits the anti-neoplastic effects of HDAC inhibitors

Fujii, K., Suzuki, N., Jimura, N., Idogawa, M., Kondo, T., Iwatsuki, K., & Kanekura, T. (2018) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2018.01.002 · Cited by 5 · see citing works

Epigenetic Regulation in Overcoming Chemoresistance

(2021) · Elsevier eBooks · doi:10.1016/c2020-0-00433-0 · Cited by 5 · see citing works

Epigenetic alteration contributes to the transcriptional reprogramming in T-cell prolymphocytic leukemia

Tian, S., Zhang, H., Zhang, P., Kalmbach, M. T., Lee, J., Ördög, T., Hampel, P. J., Call, T. G., Witzig, T. E., Kay, N. E., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-87890-9 · Cited by 4 · see citing works

Targeted epigenetic modulation using a DNA‐based histone deacetylase inhibitor enhances cardiomyogenesis in mouse embryonic stem cells

Lee, J. A., An, J., Taniguchi, J., Kashiwazaki, G., Pandian, G. N., Parveen, N., Kang, T. M., Sugiyama, H., De, D., & Kim, K. K. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.30140 · Cited by 3 · see citing works

Histone Deacetylase Inhibitors Enhance CRISPR‐Cas9 Cutting Efficiency

Bjornson, Y. M., Huang, C. Y., Castañeda, G. A. L., & Yamomoto, E. (2020) · The FASEB Journal · doi:10.1096/fasebj.2020.34.s1.06164 · Cited by 2 · see citing works

Promising strategies: Combination of epigenetic inhibitors for cancer therapy

Gronemeyer, H. (2020) · International Journal of Cancer · doi:10.1002/ijc.33142 · Cited by 2 · see citing works

Targeting epigenetic regulators to overcome drug resistance in cancers

Wang, N., Ma, T., & Yu, B. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01341-7 · Cited by 319 · see citing works

Recent histone deacetylase inhibitors in cancer therapy

Parveen, R., Harihar, D., & Chatterji, B. P. (2023) · Cancer · doi:10.1002/cncr.34974 · Cited by 171 · see citing works

Epigenetic modifications: Key players in cancer heterogeneity and drug resistance

Sadida, H. Q., Abdulla, A., Marzooqi, S. A., Hashem, S., Macha, M. A., Akil, A. S. A.-S., & Bhat, A. A. (2024) · Translational Oncology · doi:10.1016/j.tranon.2023.101821 · Cited by 151 · see citing works

Polyphenols as Potent Epigenetics Agents for Cancer

Rajendran, P., Abdelsalam, S. A., Renu, K., Veeraraghavan, V., Ammar, R. B., & Ahmed, E. A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911712 · Cited by 115 · see citing works

Current Molecular Combination Therapies Used for the Treatment of Breast Cancer

Wang, Y., & Minden, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911046 · Cited by 110 · see citing works

Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma: A Physiopathologic and Pharmacologic Review

Koltai, T., Reshkin, S. J., Carvalho, T. M. A., Molfetta, D. D., Greco, M. R., Alfarouk, K. O., & Cardone, R. A. (2022) · Cancers · doi:10.3390/cancers14102486 · Cited by 107 · see citing works

Cell death pathways: molecular mechanisms and therapeutic targets for cancer

Wang, S., Guo, S., Guo, J., Du, Q., Wu, C., Wu, Y., & Zhang, Y. (2024) · MedComm · doi:10.1002/mco2.693 · Cited by 90 · see citing works

Double‐strand DNA break repair: molecular mechanisms and therapeutic targets

Tan, J., Sun, X., Zhao, H., Guan, H., Gao, S., & Zhou, P. (2023) · MedComm · doi:10.1002/mco2.388 · Cited by 96 · see citing works

Selective HDAC3 Inhibitors with Potent In Vivo Antitumor Efficacy against Triple-Negative Breast Cancer

Pulya, S., Himaja, A., Paul, M., Adhikari, N., Banerjee, S., Routholla, G., Biswas, S., Jha, T., & Ghosh, B. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00614 · Cited by 63 · see citing works

Current trends in development of HDAC-based chemotherapeutics

Cheshmazar, N., Hamzeh‐Mivehroud, M., Charoudeh, H. N., Hemmati, S., Melesina, J., & Dastmalchi, S. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120946 · Cited by 57 · see citing works

A deep learning model of tumor cell architecture elucidates response and resistance to CDK4/6 inhibitors

Park, S., Silva, E., Singhal, A., Kelly, M. R., Licon, K. S., Panagiotou, I., Fogg, C., Fong, S. H., Lee, J. J. Y., Zhao, X., et al. (2024) · Nature Cancer · doi:10.1038/s43018-024-00740-1 · Cited by 60 · see citing works

Epigenetic regulators combined with tumour immunotherapy: current status and perspectives

Zhang, H., Pang, Y., Yi, L., Wang, X., Wei, P., Wang, H., & Lin, S. (2025) · Clinical Epigenetics · doi:10.1186/s13148-025-01856-6 · Cited by 43 · see citing works

Update on histone deacetylase inhibitors in peripheral T-cell lymphoma (PTCL)

Lu, G., Jin, S., Lin, S.-W., Gong, Y., Zhang, L., Yang, H. J., Mou, W., & Du, J. (2023) · Clinical Epigenetics · doi:10.1186/s13148-023-01531-8 · Cited by 39 · see citing works

HDAC inhibitors enhance the anti-tumor effect of immunotherapies in hepatocellular carcinoma

Shen, C., Li, M., Duan, Y., Jiang, X., Hou, X., Xue, F., Zhang, Y., & Luo, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1170207 · Cited by 36 · see citing works

Application of nanoparticles in breast cancer treatment: a systematic review

Bourang, S., Noruzpour, M., Godekahriz, S. J., Ebrahimi, H. A., Amani, A., Zakaria, R. A., & Yaghoubi, H. (2024) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-024-03082-y · Cited by 35 · see citing works

JMJD8 Is an M2 Macrophage Biomarker, and It Associates With DNA Damage Repair to Facilitate Stemness Maintenance, Chemoresistance, and Immunosuppression in Pan-Cancer

Liang, X., Zhang, H., Wang, Z., Zhang, X., Dai, Z., Zhang, J., Luo, P., Zhang, L., Hu, J. J., Liu, Z., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.875786 · Cited by 35 · see citing works

Advancements in Osteosarcoma Therapy: Overcoming Chemotherapy Resistance and Exploring Novel Pharmacological Strategies

Zhra, M., Akhund, S. A., & Mohammad, K. S. (2025) · Pharmaceuticals · doi:10.3390/ph18040520 · Cited by 36 · see citing works

Advances of HDAC inhibitors in tumor therapy: potential applications through immune modulation

Tian, J., Han, M., Song, F., Liu, Y., Shen, Y., & Zhong, J. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1576781 · Cited by 32 · see citing works

Are inhibitors of histone deacetylase 8 (HDAC8) effective in hematological cancers especially acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL)?

Amin, S. A., Khatun, S., Gayen, S., Das, S., & Jha, T. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115594 · Cited by 31 · see citing works

Bayesian Optimization over Multiple Experimental Fidelities Accelerates Automated Discovery of Drug Molecules

McDonald, M. A., Koscher, B. A., Canty, R. B., Zhang, J. J., Ning, A., & Jensen, K. F. (2025) · ACS Central Science · doi:10.1021/acscentsci.4c01991 · Cited by 30 · see citing works

Histone deacetylase inhibitors for leukemia treatment: current status and future directions

Hosseini, M., Sanaat, Z., Akbarzadeh, M. A., Vaez-Gharamaleki, Y., & Akbarzadeh, M. (2024) · European journal of medical research · doi:10.1186/s40001-024-02108-8 · Cited by 29 · see citing works

Unlocking the epigenetic code: new insights into triple-negative breast cancer

Mahendran, G., Shangaradas, A. D., Romero-Moreno, R., Dona, N. W., Sarasija, S. H. G. S., Perera, S., & Silva, G. N. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1499950 · Cited by 25 · see citing works

The epigenetic revolution in hematology: from benchside breakthroughs to clinical transformations

Esfahani, M. A., Servatian, N., Al-Athari, A. J. H., Khafaja, E. S. M., Seraji, H. R., & Samarkhazan, H. S. (2025) · Clinical and Experimental Medicine · doi:10.1007/s10238-025-01783-z · Cited by 24 · see citing works

Research progress of STAT3-based dual inhibitors for cancer therapy

Yang, X.-J., Xu, L., Yang, L., & Xu, S. (2023) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2023.117382 · Cited by 23 · see citing works

Epigenetic marvels: exploring the landscape of colorectal cancer treatment through cutting-edge epigenetic-based drug strategies

Tahghighi, A., Seyedhashemi, E., Mohammadi, J., Moradi, A., Esmaeili, A., Pornour, M., Jafarifar, K., & Ganji, S. M. (2025) · Clinical Epigenetics · doi:10.1186/s13148-025-01844-w · Cited by 21 · see citing works

Roles of PPAR activation in cancer therapeutic resistance: Implications for combination therapy and drug development

Zhang, Y., Xiao, B., Liu, Y., Wu, S., Xiang, Q., Xiao, Y., Zhao, J., Yuan, R., Xie, K., & Li, L. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.176304 · Cited by 22 · see citing works

Acetylation: a new target for protein degradation in cancer

Crawford, C. E. W., & Burslem, G. M. (2025) · Trends in Cancer · doi:10.1016/j.trecan.2025.01.013 · Cited by 20 · see citing works

NLRP3 Inflammasome-Mediated Osteoarthritis: The Role of Epigenetics

Liu, Y., Wang, Y., Yan, P., Cui, N., Xu, K., Liu, D., Yuan, T., & Cao, L. (2025) · Biology · doi:10.3390/biology14010071 · Cited by 17 · see citing works

Discovery of novel, potent, and orally bioavailable HDACs inhibitors with LSD1 inhibitory activity for the treatment of solid tumors

Duan, Y., Yu, T., Jin, L., Zhang, S., Shi, X., Zhang, Y., Zhou, N., Xu, Y., Lu, W., Zhou, H., et al. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115367 · Cited by 17 · see citing works

Epigenetic-based combination therapy and liposomal codelivery overcomes osimertinib-resistant NSCLC via repolarizing tumor-associated macrophages

Lin, T., Xiong, W., Chen, G., He, Y., Li, L., Gao, X., Zhou, J., Lv, W.-W., & Huang, Y. (2023) · Acta Pharmacologica Sinica · doi:10.1038/s41401-023-01205-4 · Cited by 16 · see citing works

The Roles of Histone Deacetylases in the Regulation of Ovarian Cancer Metastasis

Xu, L., Yan, X., Wang, J., Zhao, Y., Liu, Q., Fu, J., Shi, X., & Su, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242015066 · Cited by 16 · see citing works

Histone methylation and acetylation in cancer: mechanism, progression, and targets

Bu, S., Ye, T., Gao, H., Song, H., & Zhu, Y. (2024) · ONCOLOGIE · doi:10.1515/oncologie-2024-0324 · Cited by 14 · see citing works

HDAC8 As an Emerging Target in Drug Discovery With Special Emphasis on Medicinal Chemistry

Rajaraman, S., Balakrishnan, R., Deshmukh, D., Ganorkar, A., Biswas, S., Pulya, S., & Ghosh, B. (2023) · Future Medicinal Chemistry · doi:10.4155/fmc-2023-0054 · Cited by 13 · see citing works

Current clinical trials for epigenetic targets and therapeutic inhibitors for pancreatic cancer therapy

Ganji, C., & Farran, B. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.12.013 · Cited by 13 · see citing works

Discovery of novel itaconimide-based derivatives as potent HDAC inhibitors for the efficient treatment of prostate cancer

Jiang, Q., Tang, Y.-J., Hu, Q.-L., Wang, B., Ruan, X.-Q., & Zhou, Q. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116315 · Cited by 13 · see citing works

Deciphering the Therapeutic Potential of Novel Pentyloxyamide-Based Class I, IIb HDAC Inhibitors against Therapy-Resistant Leukemia

Fischer, F., Schliehe‐Diecks, J., Tu, J., Gangnus, T., Ho, Y. L., Hebeis, M., Avelar, L. A. A., Scharov, K., Watrin, T., Kemkes, M., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02024 · Cited by 12 · see citing works

CRISPR/Cas9-directed epigenetic editing in colorectal cancer

Gupta, M. K., Gouda, G., Moazzam‐Jazi, M., Vadde, R., Nagaraju, G. P., & El‐Rayes, B. F. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189338 · Cited by 12 · see citing works

Valproic acid as a radio-sensitizer in glioma: A systematic review and meta-analysis

Sullivan, J., Fahey, P. P., Agho, K. E., Hurley, S. P., Feng, Z., Day, R. O., & LIM, D. J. (2022) · Neuro-Oncology Practice · doi:10.1093/nop/npac078 · Cited by 11 · see citing works

An assembly-inducing PDC enabling the efficient nuclear delivery of nucleic acid for cancer stem-like cell suppression

Wang, D., Tian, Y., Zhang, Y., Sun, X., Wu, Y., Liu, R., Zeng, F., Du, J., & Hu, K. (2022) · Nanoscale · doi:10.1039/d2nr02118h · Cited by 11 · see citing works

Clinical progress and functional modalities of HDAC inhibitor-based combination therapies in cancer treatment

Talom, A., Barhoi, A., Jirpu, T., Dawn, B., & Ghosh, A. (2025) · Clinical & Translational Oncology · doi:10.1007/s12094-025-03995-x · Cited by 10 · see citing works

Epigenetic regulation in colorectal cancer: The susceptibility of microRNAs 145, 143 and 133b to DNA demethylation and histone deacetylase inhibitors

Omar, A., Govan, D., & Penny, C. B. (2023) · PLoS ONE · doi:10.1371/journal.pone.0289800 · Cited by 8 · see citing works

A review of the potential use of melatonin in cancer treatment: Data analysis from Clinicaltrials.gov

Alshehri, F. S., & Althobaiti, Y. S. (2024) · Medicine · doi:10.1097/md.0000000000040517 · Cited by 8 · see citing works

Tumor necrosis factor‑related apoptosis‑inducing ligand is a novel transcriptional target of runt‑related transcription factor 1

Yoshida, T., Yamasaki, K., Tadagaki, K., Kuwahara, Y., Matsumoto, A., Sofovic, A., Kondo, N., Sakai, T., & Okuda, T. (2021) · International Journal of Oncology · doi:10.3892/ijo.2021.5296 · Cited by 8 · see citing works

Tubulin-based dual-target compounds and protein degraders for cancer therapy—An updated review (2021-present)

Li, S., Liu, Z., Li, T., Tang, Z., Feng, Y., Chen, C., Gu, C., & Chen, J. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118191 · Cited by 7 · see citing works

Tracking intracellular nuclear targeted-chemotherapy of chidamide-loaded Prussian blue nanocarriers by SERS mapping

Xing, X., Zhong, W., Tang, P., Tao, Q., Lü, X., & Zhong, L. (2023) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2023.113469 · Cited by 7 · see citing works

Research progress of LSD1-based dual-target agents for cancer therapy

Yang, X. (2024) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2024.117651 · Cited by 6 · see citing works

Common Applications of Black Cumin Seed (Nigella sativa) Oil in Folk Medicine

Hosni, R., Haffez, H., & Elkordy, H. (2023) · Journal of Advanced Pharmacy Research · doi:10.21608/aprh.2022.166251.1196 · Cited by 6 · see citing works

Thymidine phosphorylase associates with DNA damage repair to facilitate stemness maintenance, chemoresistance, and immunosuppression in pan-cancer

Liao, P., Han, Z., Yan, B., Chen, F., & Lei, P. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.145707 · Cited by 5 · see citing works

Research progress of multi-target HDAC inhibitors blocking the BRD4-LIFR-JAK1-STAT3 signaling pathway in the treatment of cancer

Jia, S., Jia, Y., Liang, S., & Wu, L. (2024) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2024.117827 · Cited by 5 · see citing works

Discovery of cloxiquine derivatives as potent HDAC inhibitors for the treatment of melanoma via activating PPARγ

Yang, L., Ding, R., Tong, X., Shen, T., Jia, S., Yan, X., Zhang, C., & Wu, L. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.117029 · Cited by 5 · see citing works

Molecular simulations required to target novel and potent inhibitors of cancer invasion

Lu, T., Li, T., Wu, M., Zheng, C.-C., He, X., Zhu, H., Li, L., & Man, R. (2023) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2023.2254695 · Cited by 5 · see citing works

Epigenetic remodeling via HDAC6 inhibition amplifies anti-tumoral immune responses in myeloid leukemia cells

Schliehe‐Diecks, J., Tu, J., Stachura, P., Schaal, K., Kemkes, M., Vasileiou, E., Rüchel, N., Brandes, D., Vogt, M., Lenz, T., et al. (2026) · Cell Death and Disease · doi:10.1038/s41419-026-08541-3 · Cited by 4 · see citing works

A dual-prodrug nanogel combining Vorinostat and Pyropheophorbide a for a high efficient photochemotherapy

Jiang, W., Cheng, Y., Hou, L., Huang, Y., Wang, S., Zhang, Y., Jiang, T., Yang, F., & Ma, Z. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.124422 · Cited by 4 · see citing works

Emerging roles of histone deacetylases in adaptive thermogenesis

Zhou, R., Cao, Y., Xiang, Y., Fang, P., & Shang, W. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1124408 · Cited by 4 · see citing works

A New Look at the Role of Radiation-Related Epigenetic Mechanisms in Diagnosis and Anticancer Therapies

Olichwier, A. J., Bruzgo-Grzybko, M., Kalita, I. S., Bielicka, N., Chabielska, E., & Gromotowicz‐Poplawska, A. (2025) · Cells · doi:10.3390/cells14231885 · Cited by 3 · see citing works

Targeting mitochondrial metabolism to overcome hormone resistance in breast cancer

Neamah, A. S., Lafta, F. M., & Wadan, A. S. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04487-z · Cited by 3 · see citing works

Histone deacetylase inhibitor use as a radiosensitizer in solid organ malignancies: a systematic review protocol

Sullivan, J., Feng, Z., Fahey, P. P., Agho, K., Hurley, S. P., & LIM, D. J. (2022) · JBI Evidence Synthesis · doi:10.11124/jbies-21-00466 · Cited by 3 · see citing works

Immunohistochemical expression of histone modification pattern in adult glioblastoma

Archana, B., D’Cruze, L., Sundaram, S., Ramanathan, K., & Ganesh, K. (2022) · Journal of Cancer Research and Therapeutics · doi:10.4103/jcrt.jcrt_257_22 · Cited by 3 · see citing works

Effects of a novel HDAC6-selective inhibitor’s radiosensitization on cancer cells

Hu, H., Wang, Q., Zhang, Y., Yang, S., Shen, A., Yan, J., Zhao, D., & Hu, B. (2024) · Molecular Biology Reports · doi:10.1007/s11033-024-10084-9 · Cited by 3 · see citing works

Butyrate blocks cell cycle progression in colorectal cancer organoids partially through HDAC2 inhibition

Liu, B., Huang, Y., Wang, X., Liu, X., Luo, Y., Wang, N., Tian, H., Huang, L., Xu, Z., Lang, J., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1788434 · Cited by 2 · see citing works

Tumors derived from lung cancer cells respond differently to treatment with sodium valproate (a HDAC inhibitor) in a chicken embryo chorioallantoic membrane model.

Diržiuvienė, R., Šlekienė, L., Palubinskienė, J., Balnytė, I., Lasienė, K., Stakišaitis, D., & Valančiūtė, A. (2022) · PubMed · doi:10.14670/hh-18-482 · Cited by 2 · see citing works

Synergistic effect of docetaxel combined with a novel multi-target inhibitor CUDC-101 on inhibiting human prostate cancer

Li, Z., Quan, C., Li, W., & Ji, M. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.154938 · Cited by 2 · see citing works

Clinical Significance of the Immunohistochemical Expression of Histone Deacetylases (HDACs)-2, -4, and -5 in Ovarian Adenocarcinomas

Levidou, G., Arsenakis, D., Bolovis, D. I., Meyer, R., Brucker, C. V. M., Papadopoulos, T., & Theocharis, S. E. (2024) · Biomedicines · doi:10.3390/biomedicines12050947 · Cited by 2 · see citing works

Histone Deacetylase Inhibitor Panobinostat Augments the Antitumor Efficacy of Bromodomain Inhibitor JQ1 by Hijacking Mechanisms of Apoptosis in Head Neck Squamous Cell Carcinoma

Feng, X., Huang, X., Zhang, S., Wu, M., Zhou, W., Jin, F., Dai, C., & Zhang, W. (2025) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-025-01941-w · Cited by 1 · see citing works

Trametinib and Fimepinostat Induce Malignant Peripheral Nerve Sheath Tumor Cell Death In Vitro

Hass, E. W., Oliveira, S. A., & Fernández‐Valle, C. (2026) · Cancers · doi:10.3390/cancers18050746 · Cited by 1 · see citing works

Thieno[3,2-d]pyrimidines in Anticancer Drug Discovery: Recent Advances in Drug Design and Molecular Targets

Buronov, A., Gaybullaev, S., Murtazaeva, Z., Ruzieva, F., Khushnazarov, Z., Turgunov, D., Nasrullaev, A., Kuryazov, R., Takhirov, Y. R., Tursunov, F., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27167457 · Cited by 1 · see citing works

Epigenetic therapies: histone deacetylases

Blanquart, C. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-91367-6.00022-2 · Cited by 1 · see citing works

Time-dependent chromatin maturation during 3D spheroid culture improves preclinical modeling of non-small cell lung cancerPreprint

Darracq, A., Sgarioto, N., Huot, M., McInnes, G., Méant, A., Langford‐Avelar, A., Villarreal, O. D., Marois, F., Caron, M., St-Onge, P., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.01.23.634518

Reflections and perspectives on epigenetically mediated biological control: compromises in cancer and skeletal pathology

Stein, G. S. (2025) · Academia Biology · doi:10.20935/acadbiol7628

Marine natural products and their anticancer potential via histone deacetylases inhibition in breast cancer

(2025) · Studies in natural products chemistry · doi:10.1016/b978-0-443-23754-6.00006-9

HDAC Inhibitors Enhance the Chemosensitivity of Osteosarcoma Cells to Etoposide by Suppressing the Hippo/YAP Signaling Pathway

Cao, Z., Chen, Y., Chen, M., Fan, Q., Sun, H., Jin, D., Liu, Y., Xiong, Y., & Wang, D. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26188935

Time-dependent epigenomic changes during 3D spheroid culture improve the preclinical modeling of non-small cell lung cancerPreprint

Darracq, A., Sgarioto, N., Huot, M., McInnes, G., Méant, A., Langford‐Avelar, A., Villarreal, O. D., Marois, F., Caron, M., St-Onge, P., et al. (2025) · Research Square · doi:10.21203/rs.3.rs-8000509/v1

Quercetin-3-O-galactoside from Garcinia Kola Heckel stem bark as a potential bioactive inhibitor against histone deacetylase 8 (HDAC8) using in silico study

Adeniran, A. A., Adenaya, A. A., Ogunlakin, A. D., Prabhu, D., & Sonibare, M. A. (2025) · Discover Chemistry. · doi:10.1007/s44371-025-00393-8

The Epigenetic Angle in the Precision Medicine Era for Blood Disorder Advancements

Hamdy, N. Μ., Abulsoud, A. I., Rizk, N. I., AL‐Noshokaty, T. M., Zaki, M. B., Sultan, A. S., & Doghish, A. S. (2026) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-3-032-08530-6_6

DNA methylation and histone modification in liver cancer

Gouda, G., Gupta, M., & Vadde, R. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-27765-8.00016-3

Design, synthesis and biological evaluation of Chidamide derivatives against breast cancer

Zhou, Y., Lang, Z., Lin, H., Wang, J., Zhang, B., Asan, K., Wang, X., Sun, L., & Ji, J. (2026) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2026.130652

The Role of Epigenetics in Cancer Progression

Biswas, P., Sridhar, B., Saha, A., Sudha, M., & Kulkarni, M. (2026) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9798898814113126010006

Macrocyclic histone deacetylase inhibitor-based near-infrared-responsive ionic nanomedicines for enhanced cancer therapy

Oyebade, A., Hossain, R., Hassan, M., Oluremi, A., Rahman, S., Ali, N., Griffin, R. J., Oyelere, A. K., & Siraj, N. (2026) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2026.127045

Epigenetic therapy by phytochemicals in lung cancer: Mechanism, therapeutic potential, and clinical implications

Bhushan, R., Gupta, P., Dhurve, A., Bhardwaj, K., Kumar, U., Gupta, S. K., & Yadav, P. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-45146-1.00022-9

Discovery of novel NQO1/STAT3/HDAC triple-target agents for the treatment of triple negative breast cancer

Li, S., Ma, D., Han, Z., Zhang, C., & Wu, L. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.110146

Artemisinin-derived hydrophobic tags: structural modification and structure-activity relationship exploration of HDAC6/1 targeting degraders with potent antileukemic efficacy

Wang, C., Yu, Q., Lu, X., Yang, Y., Li, Y., Sun, X., He, H., Zhang, S., & Zhong, H. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.110275

Drug resistance in cancer radiotherapy: From mechanisms to overcoming strategies

Chen, Y., Cai, C., Xu, X.-C., Yang, Z., Li, J., Pan, Q., Wang, L., Luo, W., Chen, Z., Zeng, L., et al. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108380

HDAC inhibitors in cancer therapy: sensitization mechanisms, combination strategies, and translational challenges

Liu, K.-Y., Zhao, X., Liu, J., Li, M.-N., Cui, H., Wang, Z., & Zhou, X. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1951750

BindingDB Entry 50019624: Research progress of LSD1-based dual-target agents for cancer therapy.

BindingDB (2024) · UC San Diego · doi:10.7270/q2ff3xr9

BindingDB Entry 50021879: Research progress of multi-target HDAC inhibitors blocking the BRD4-LIFR-JAK1-STAT3 signaling pathway in the treatment of cancer.

BindingDB (2025) · UC San Diego · doi:10.7270/q2gh9pnb

BindingDB Entry 50022889: Discovery of cloxiquine derivatives as potent HDAC inhibitors for the treatment of melanoma via activating PPARγ.

BindingDB (2026) · UC San Diego · doi:10.7270/q2hm5f9s

BindingDB Entry 50019365: Discovery of novel, potent, and orally bioavailable HDACs inhibitors with LSD1 inhibitory activity for the treatment of solid tumors.

BindingDB (2024) · UC San Diego · doi:10.7270/q2j96brz

BindingDB Entry 50020302: Selective HDAC3 Inhibitors with Potent In Vivo Antitumor Efficacy against Triple-Negative Breast Cancer.

BindingDB (2024) · UC San Diego · doi:10.7270/q2s46xfd

BindingDB Entry 50019392: Research progress of STAT3-based dual inhibitors for cancer therapy.

BindingDB (2024) · UC San Diego · doi:10.7270/q2tm7ghf

BindingDB Entry 50022870: Deciphering the Therapeutic Potential of Novel Pentyloxyamide-Based Class I, IIb HDAC Inhibitors against Therapy-Resistant Leukemia.

BindingDB (2026) · UC San Diego · doi:10.7270/q2zs32c4

BindingDB Entry 50022324: Are inhibitors of histone deacetylase 8 (HDAC8) effective in hematological cancers especially acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL)?

BindingDB (2025) · UC San Diego · doi:10.7270/q2r2163b

BindingDB Entry 50021174: Discovery of novel itaconimide-based derivatives as potent HDAC inhibitors for the efficient treatment of prostate cancer.

BindingDB (2025) · UC San Diego · doi:10.7270/q2p273r8

HDAC inhibitors in cancer therapy: sensitization mechanisms, combination strategies, and translational challenges

Liu, K.-Y., Zhao, X., Liu, J., Li, M.-N., Cui, H., Wang, Z., & Zhou, X. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1951750

Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi

Suraweera, A., O'Byrne, K. J., & Richard, D. J. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00092 · Cited by 671 · see citing works

Histone deacetylase inhibitors in cancer therapy. A review

Hraběta, J., Stiborová, M., Adam, V., Kizek, R., & Eckschlager, T. (2013) · Biomedical Papers · doi:10.5507/bp.2013.085 · Cited by 61 · see citing works

Rational Therapeutic Combinations with Histone Deacetylase Inhibitors for the Treatment of Cancer

Thurn, K. T., Thomas, S., Moore, A. P., & Münster, P. N. (2011) · Future Oncology · doi:10.2217/fon.11.2 · Cited by 249 · see citing works

Histone Deacetylase Inhibitors; An Overview of the Clinical Studies in Hematological Malignancies and Solid Tumors

Pojani, E., Bozo, S., & Mehmeti, I. (2022) · Albanian Journal of Natural and Technical Sciences · doi:10.67537/ajnts2701013